The Group comprises a Point-of-Care Division in Oslo, a Laboratory Division in Dundee and local distribution subsidiaries in the UK (Axis-Shield UK), in Norway, Sweden, Denmark and Finland (Medinor), in Switzerland (Axis-Shield AG) and in Germany (Axis-Shield GmbH) and most of these companies also sell third-party products and non-IVD medical devices. We also have a representative office in China and a growing organisation in the USA which is primarily charged with accelerating the Afinion placement programme.
At the point of care, our products include the NycoCard range and the Afinion. In the laboratory sector we specialise in proprietary markers for the early diagnosis and management of critical illnesses such as cardiovascular and neurodegenerative diseases, rheumatoid arthritis and diabetes. We are playing an increasingly leading role in the fight against the global diabetes epidemic, and the need to keep tight control over blood glucose levels to avoid serious clinical sequelae.
We have a special skill in adapting our markers to the automated analyser systems of the global IVD companies which dominate the hospital laboratory sector.
We firmly believe that our products provide clinicians and other healthcare professionals with tools to deliver better patient care. Early, rapid and differential diagnosis of disease in the presence of the patient facilitates the best treatment options and is being increasingly recognised as an essential component of more effective primary care.
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.
Axis-Shield's award winning point-of-care test system is designed for maximum simplicity coupled with laboratory accuracy and reliability for a number of key markers important for improved patient management.